The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | ANDROMEDA: daratumumab + CyBorD for AL amyloidosis
Efstathios Kastritis
• 16 Jun 2020
Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses the Phase III ANDROMEDA study (NCT03201965) investigating subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed amyloid light chain (AL) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
